The Effect of Vitamin D Supplementation on Glycemic Control in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Insulin 2 endocrinologydiseasesdrugs
calcitriol 1 endocrinologydiseasesdrugs
ergocalciferol 2 endocrinologydiseasesdrugs
obesity 2 endocrinologydiseases
paricalcitol 1 endocrinologydiseasesdrugs
cholecalciferol 3 endocrinologydiseasesdrugs
diabetes mellitus 1 endocrinologydiseases
doxercalciferol 1 endocrinologydiseasesdrugs
hyperglycemia 1 endocrinologydiseases
hyperparathyroidism 1 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 13218 months, other Asians, normal BMI, and baseline vitamin D deficient (Table 2).3.7. The Effect of Fasting Insulin Only four (n = 364) out of 20 randomized controlled trials measured fasting insulin [[21],[25],[26],[38]].
Insulin 28451 insulin.nutrients-10-00375-t002_Table 2Table 2Subgroup analyses.SubgroupsSerum Vitamin D FBG 1HbA1c 1HOMA-IR 1Fasting Insulin WMD 195%CIpWMD95%CIpWMD95%CIpSMD95%CIpSMD95%CIpEthnicityMiddle Easterners40.03(27.71, 52.34)<0.001−10.43(−14.80,
calcitriol 6242 cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR paricalcitol OR doxercalciferol OR calcitriol OR 25-Hydroxyvitamin D) AND (diabetes OR diabetes mellitus OR T2DM OR hyperglycemia OR hyperglycaemia
cholecalciferol 4601 effect of vitamin D supplementation in T2D patients; (2) used oral vitamin D formulations containing cholecalciferol or ergocalciferol; (3) reported at least one of the following primary outcomes of interest: serum 25(OH)D
cholecalciferol 6137 trial OR controlled trial OR RCT NOT review NOT animal) AND (vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR paricalcitol OR doxercalciferol OR calcitriol
cholecalciferol 22207 study is that we only included randomized controlled trials with oral vitamin D supplementation, mainly cholecalciferol ; thus, the relative uniformity of the study design and formulation of vitamin D reduced the overall
doxercalciferol 6223 vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR paricalcitol OR doxercalciferol OR calcitriol OR 25-Hydroxyvitamin D) AND (diabetes OR diabetes mellitus OR T2DM OR hyperglycemia OR
ergocalciferol 4620 supplementation in T2D patients; (2) used oral vitamin D formulations containing cholecalciferol or ergocalciferol ; (3) reported at least one of the following primary outcomes of interest: serum 25(OH)D concentration,
ergocalciferol 6156 trial OR RCT NOT review NOT animal) AND (vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR paricalcitol OR doxercalciferol OR calcitriol OR 25-Hydroxyvitamin
paricalcitol 6207 OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR paricalcitol OR doxercalciferol OR calcitriol OR 25-Hydroxyvitamin D) AND (diabetes OR diabetes mellitus OR T2DM
Select Disease Character Offset Disease Term Instance
diabetes mellitus 6294 alfacalcidol OR paricalcitol OR doxercalciferol OR calcitriol OR 25-Hydroxyvitamin D) AND (diabetes OR diabetes mellitus OR T2DM OR hyperglycemia OR hyperglycaemia OR glucose OR HbA1c OR glycated hemoglobin OR insulin resistance
hyperglycemia 6323 doxercalciferol OR calcitriol OR 25-Hydroxyvitamin D) AND (diabetes OR diabetes mellitus OR T2DM OR hyperglycemia OR hyperglycaemia OR glucose OR HbA1c OR glycated hemoglobin OR insulin resistance OR insulin sensitivity
hyperparathyroidism 5154 that could potentially alter vitamin D metabolism (e.g., chronic kidney disease Stage 4 or higher, or hyperparathyroidism ); (3) studies involving participants < 18 years; (4) studies in which non placebo controls, such as
obesity 12603 had high heterogeneity (p < 0.001; I2 = 92%). Nevertheless, effects shown in other ethnicities and obesity subgroups were significantly in favor of the control group (Table 2). 3.6. The Effect on HOMA-IRThe
obesity 13728 normal BMI, vitamin D dose ≤ 2000 IU/day and baseline HbA1c > 7%. In contrast, other ethnicities and obesity subgroups showed preferred changes that were significantly in favor of the control group (Table 2).

You must be authorized to submit a review.